#biotechnology #biospace #lifesciences #pharmaceuticals #clinicalcatchup
Clinical trial, Pharmaceutical industry, Pharmacology, Informed consent, Immune system, Good clinical practice
Clinical Catch-Up: January 25-29
It was a busy week for clinical trial news. Read on for more information.
Clinical Catch-Up: January 25-29
It was a busy week for clinical trial news. Read on for more information.
We are sorry, we could not find the related article
If you are curious about Biotech Essentials, the Influencers Review and Companies & Industries
Please click on:
Or signup to our newsletters
Other Essentials
AI Essentials
Robotics
Robotics
Ethics
Ethics
Research
Research
Applied Use Cases
Applied Use Cases
Marketing
Marketing
Healthcare
Healthcare
Cybersecurity
Cybersecurity
Clinical Catch-Up: June 22-26
It was a busy week for clinical trial updates. Here’s a look.
Catching Up to Coronavirus: Top 60 Treatments in Development
GEN A-List shows 60 active COVID-19 drug development programs in North America, Europe, and China. More than two dozen of these treatments have emerged or been made public just in the two ...
Increasing number of biopharma drugs target COVID-19 as virus spreads
In a flurry of catch-up following the coronavirus outbreak in China, a number of biopharma companies have announced development within the last few weeks to address the ever-spreading ...
Covid-19: what treatments are being investigated?
With no current specific treatment for covid-19, the race is on to develop or repurpose drugs to help end the epidemic. The World Health Organization has now launched the SOLIDARITY trial ...
A Year to Remember: The Biggest European Biotech News in 2020
The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled through. Let’s look back at some of the top moments in the last 12 months. After the many ...
As Rhythm Pharmaceuticals preps for first approval, CEO hits the exit
Fierce 15 winner Rhythm Pharmaceuticals is on the cusp of gaining its first approval in 2020, but it will be ushering in this potential milestone without its chief.
Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19
Independent Data Monitoring Committee recommended on September 30, 2020 that the study continue into Phase 3 based on a positive evaluation of safety and tolerability data from the Phase 2 ...
Vir Biotechnology and GSK announce start of NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19
Global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalised adults with COVID-19
Merck & Co adds COVID-19 drug to pipeline with OncoImmune buy
Merck & Co is to buy US biotech OncoImmune for at least $425m, adding a potential new therapy for COVID-19 to its pipeline.
The drugs and treatments that could stop Covid-19
More than 70 clinical trials have registered with the Food and Drug Administration.
Ideas for an FDA Reboot
The FDA needs to get healthy, and fast. Its credibility as the world’s No. 1 science-based regulator of food and drugs has been tarnished. From the start, it had to play catch-up on RT-PCR ...
Finally, some good news about Ebola: Two new treatments dramatically lower the death rate in a trial
The therapies, both monoclonal antibody preparations, will now be used to treat all patients